New Pancreatic Cancer Drug Transforms Lives After 50 Years

For 36-year-old gymnastics manager Leanna Stokes, two syllables became her lifeline: KAY-ras.

When doctors diagnosed Stokes with metastatic pancreatic cancer, one of oncology's most devastating diagnoses, her oncologist kept mentioning KRAS. This gene mutation makes cancers more aggressive, but it also held the key to a revolutionary new treatment.

"She always mentioned this, KRAS, KRAS, KRAS," Stokes said. "As Stokes proceeded to receive line after line of chemotherapy, she would remind herself, 'It's there. It's there. It's there. Then finally, it was my turn.'"

Scientists have struggled for nearly 50 years to create drugs that could target KRAS mutations. When biochemist Kevan Shokat at the University of California, San Francisco finally cracked the code, the first drugs were disappointing. They helped only about 1% of pancreatic cancer patients, and resistance formed quickly.

But Shokat's breakthrough proved it could be done. Companies jumped into developing better KRAS drugs, with Revolution Medicines leading the charge with daraxonrasib.

This is the drug that changed Stokes' life. She enrolled in a clinical trial and the results transformed her outlook, enabling her to live far longer than most patients with her diagnosis.

Why This Inspires

Oncologists and drug developers are calling this a new era for pancreatic cancer medicine. The breakthrough doesn't just help pancreatic cancer patients. KRAS mutations appear in lung, colorectal, and endometrial cancers too, meaning millions more patients could benefit.

Dozens of companies are now testing promising KRAS inhibitors in clinical trials. What seemed impossible just a few years ago is becoming routine care.

For patients like Stokes who heard "KRAS, KRAS, KRAS" from their doctors, persistence paid off. After half a century of scientific struggle, hope finally arrived.